Real-world use of cenobamate in pediatric focal epilepsies and developmental epileptic encephalopathies: A multicenter retrospective series.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Soto-Insuga V
- Valls Carbó A
- Pinzón-Acevedo AG
- González-Alguacil E
- Peñas JJG
- Jamardo AS
- Aznar-Laín G
- Ibáñez-Micó S
- Martínez HA
- Buenache R
- Rekarte S
- Olivera AP
- Tuero-Montiel E
- DomínguezCarral J
- López M
- Ribes AG
- González MJM
- Arias E
- Ron AG
- Boronat S
- Viñas ET
- Casellas D
- Navarro V
- Conejo D
- Miravet E
- Román IS
- Nagel-Rein AG
- Cabeza MM
- Aledo-Serrano Á
Abstract
OBJECTIVE: Cenobamate (CNB) is an anti-seizure medication approved for focal-onset seizures in adults, with growing evidence supporting its use in pediatric drug-resistant epilepsy (DRE). This study evaluates the efficacy, retention, and safety of CNB in children and adolescents, including those with developmental and epileptic encephalopathies (DEEs). METHODS: We conducted a retrospective, multicenter study of 169 pediatric patients (0-18 years) with DRE treated with CNB across centers in Spain. Seizure response (=50% reduction) and seizure freedom (no seizures in the previous month) were assessed at 3, 6, and 12 months. RESULTS: At 12 months, CNB showed a retention rate of 89.2%, with 83.9% of patients achieving seizure response and 19.6% reaching seizure freedom. Response rates were 73.4% at 3 months and 77.1% at 6 months, with seizure freedom increasing from 11.8% at 3 months to 21.1% at 6 months. Outcomes were comparable between DEEs and focal epilepsies, indicating broad-spectrum efficacy. Seizure worsening occurred in 4.7% of patients, all with DEEs. After adjusting for seizure type, those patients with focal seizures had higher odds of achieving seizure response (odds ratio [OR] 95% confidence interval [95% CI] 5.46, 1.27-23.52; p = 0.02) and seizure freedom (OR 95% CI 5.32, 1.57-17.97; p < 0.01). Median CNB doses (mg/kg/day) were 1.78 (range 0.37-12.5), 2.5 (range 0.67-12.5), and 3.19 (range 0.96-9.09) at 3, 6, and 12 months, respectively. Adverse events occurred in 44.9% of patients, most commonly somnolence (42.3%) and dizziness (22.4%), which improved with slower titration. SIGNIFICANCE: CNB appears effective and well-tolerated in pediatric DRE, including DEE, with high retention and sustained efficacy over time. Adverse events were generally manageable with dose adjustments, and slow, weight-based titration improved tolerability. Prospective studies are warranted to confirm these findings.
© 2025 International League Against Epilepsy.
Datos de la publicación
- ISSN/ISSNe:
- 0013-9580, 1528-1167
- Tipo:
- Article
- Páginas:
- 4712-4724
- DOI:
- 10.1111/epi.18586
- PubMed:
- 40736694
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 1,893 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
EPILEPSIA WILEY
Citas Recibidas en Web of Science: 8
Documentos
- No hay documentos
Filiaciones
Keywords
- antiseizure medications; cenobamate; developmental and epileptic encephalopathies; focal seizures; pediatric epilepsy
Cita
Soto V,Valls A,Pinzón AG,González E,Peñas JJG,Jamardo AS,Aznar G,Ibáñez S,Martínez HA,Buenache R,Rekarte S,Olivera AP,Tuero E,DomínguezCarral J,López M,Ribes AG,González MJM,Arias E,Ron AG,Boronat S,Viñas ET,Casellas D,Navarro V,Conejo D,Miravet E,Román IS,Nagel AG,Cabeza MM,SMEYERS P,Aledo Á. Real-world use of cenobamate in pediatric focal epilepsies and developmental epileptic encephalopathies: A multicenter retrospective series. Epilepsia. 2025. 66. (12):p. 4712-4724. IF:5,600. (1).
Portal de investigación